Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 93-99

  Safarova, Maya S ^a   Ezhov, Marat V ^a   Afanasieva, Olga I ^a   Matchin, Yuriy G ^a   Atanesyan, Ruslan V ^a   Adamova, Irina Yu ^a   Utkina, Elena A ^a   Konovalov, Gennadiy A ^b   Pokrovsky, Sergei N ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b MEDSI Clinic 3A   (Russian Federation)

Author keywords

Angiography; Coronary atherosclerosis; Lipoprotein(a); Lp(a) apheresis; Plaque; Regression

Indexed keywords

LIPOPROTEIN A;

ADULT; ANGIOCARDIOGRAPHY; APHERESIS; ARTERY DIAMETER; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; DISEASE PROGRESSION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRROLES; RUSSIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872876060     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.015     Document Type: Article

References (24)

1. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
2. Thompson G. LDL apheresis. Atherosclerosis 2003, 167(1):1-13.
3. Thompson G. Heart-UK LDL apheresis working group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198(2):247-255.
4. Bambauer R., Bambauer C., Lehmann B., Latza R., Schiel R. LDL-apheresis: technical and clinical aspects. Scientific World Journal 2012, 2012:19. Article ID 314283.
5. Pokrovsky S.N., Adamova I.Y., Afanasieva O.I., Benevolenskaya G.F. Immunosorbent for selective removal of lipoprotein(a) from human plasma: in vitro study. Artif Organs 1991, 15:136-140.
6. Susekov A.V., Afanaséva O.I., Adamova IIu, Liakishev A.A., Kukharchuk V.V., Pokrovski S.N. Use of immunosorption for selective decrease of lipoprotein(a) levels in patients with coronary atherosclerosis. Kardiologiia 1992, 32(11-12):52-56.
7. Pokrovsky S.N., Sussekov A.V., Afanasieva O.I., et al. Extracorporeal immunoadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data. Chem Phys Lipids 1994, 67/68:323-330.
8. Thompson G., Sussekov A. Radical therapy of atherosclerosis by apheresis or liver transplantation. Atherosclerosis X 1995, 549-552. Elsevier Science, Amsterdam. F. Woodford, J. Davignon, A. Sniderman (Eds.).
9. Ullrich H., Lackner K., Schmitz G. Lipoprotein(a)-apheresis in the secondary prevention of coronary heart disease. Transfus Sci 1996, 17:511-517.
10. Bambauer R., Schiel R., Keller H.E., Klinkmann J., Latza R. Low-density lipoprotein apheresis in the treatment of two patients with coronary heart disease and extremely elevated lipoprotein(a) levels. Artif Organs 1996, 20:340-343.
11. Ullrich H., Lackner K.J., Schmitz G. Lipoprotein(a) apheresis in severe coronary heart disease: an immunoadsorption method. Artif Organs 1998, 22:135-139.
12. Straube R., Kingreen H. Lipoprotein(a) immunapheresis in the treatment of familial lipoprotein(a) hyperlipoproteinemia in a patient with coronary heart disease. Ther Apher 1998, 2:243-245.
13. Smith S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006, 113:2363-2372.
14. Pokrovsky S., Afanasieva O., Adamova I., et al. Lipoprotein(a) extracorporeal elimination by specific immunoadsorption for the treatment of CHD patients. Atherosclerosis 2000, 151(1):249.
15. Dodge J.T., Brown B.G., Bolson E.L., et al. Intrathoracic spatial location of coronary segments on the normal human heart. Circulation 1988, 78:1167-1180.
16. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
17. Ballantyne C.M., Raichlen J.S., Nicholls S.J., et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 2008, 117:2458-2466.
18. Dahlen G.H. Incidence of Lp(a) among populations. Lipoprotein(a) 1990, 151-173. Academic Press, New York. A.M. Scanu (Ed.).
19. Nielsen L.B. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis 1999, 143:229-243.
20. Maher V.G., Brown B., Marcovina S.M., Hillger L.A., Zhao X., Albers J.J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). J Am Med Assoc 1995, 274:1771-1774.
21. Jaeger B.R., Richter Y., Nagel D., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6:229-239.
22. Keller C. Apheresis in coronary heart disease with elevated Lp(a): a review of Lp(a) as a risk factor and its management. Ther Apher Dial 2007, 11:2-8.
23. Borberg H. Comparison of different Lp(a) elimination techniques: a retrospective evaluation. Transfus Apher Sci 2009, 41:61-65.
24. Bambauer R., Schiel R., Latza R. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies. Ther Apher 2000, 4:213-217.